This is a relevant topic given the frequency of encountering alcohol addiction exacerbation cases and the potential use of pharmacogenomic markers to predict patients’ response to haloperidol. However, I have some concerns for the authors to address:

1. The ms. is a bit difficult to read due to language issues. I strongly recommend a comprehensive edit of the whole manuscript in relation to language and grammar, preferably by an English speaking professional. Some of the concepts seems a bit homemade, or probably not that easy to translate into English.
2. Missing CYP2D6 genetic information for this study cohort: The FDA-approved drug label for haloperidol states that CYP2D6 and CYP3A4 genetic variability affect the clearance of haloperidol. There are currently a lot of studies conducted looking at CYP2D6 genetic polymorphism on haloperidol clearance, hence there is value in conducting studies that evaluate the effect of CYP3A genetic variations on haloperidol response. Given that prior studies have demonstrated the role of CYP2D6 on haloperidol clearance, it would be difficult to attribute the findings of this study to CYP3A genetic polymorphism alone, without accounting for the study cohort’s CYP2D6 genetic polymorphism. Is it possible for the authors to determine the study cohort’s CYP2D6 genetic profile?
3. The authors did not comment on the study limitations. Please acknowledge potential limitations of this paper (limited size, heterogeneity of other clinical characteristics, differences in baseline characterestics, etc) in the Discussion section.
4. CYP3A53: Could the authors explain why CYP3A53 was selected and the CYP3A4 alleles were not evaluated?
5. Baseline liver function: Was there a difference in baseline liver function test results between the groups that could impact the metabolism of haloperidol and other medications?
6. Baseline renal function: What was the baseline renal function of the patients? Was there a difference in renal function between the groups? This may impact the urinary cortisol collected as a biomarker of CYP3A activity (PMID 26681736).